Inclusion on list recognizes Poseida for employee sentiment and satisfaction

SAN DIEGO, Oct. 3, 2024 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced its inclusion in Newsweek Magazine’s annual America’s Top Most Loved Workplaces® list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI).

“At Poseida, our employees are essential to achieving our mission to boldly develop a new class of cell and gene therapies with the capacity to cure,” said Kristin Yarema, Ph.D., president and chief executive officer of Poseida Therapeutics. “This recognition is a testament to our outstanding and exceptionally talented team at Poseida. It is an honor to be named to Newsweek’s list of top workplaces, which reflects our strong culture and values combined with our commitment to our employees, as well as patients.”

The results were determined after surveying more than 2.6 million employees from businesses with workforces varying in size from less than 50 to more than 10,000. The list recognizes companies that put respect, caring, and appreciation for their employees at the center of their business model and, in doing so, have earned the loyalty and respect of the people who work for them. 

How positive employees feel about their future at the company, career achievement, how much employer values align with employee values, respect at all levels, and the level of collaboration at the firm were the five critical areas measured to gauge employee sentiment. In addition, areas such as inclusion, diversity, equity and belonging, career development, and company leadership were identified and analyzed in relation to the five critical areas measured.

“It’s inspiring to see the list expand this year to 200 companies, a clear indication that organizations are truly committed to creating workplaces where employees feel valued and connected. We’re thrilled to celebrate their achievements as this recognition continues to grow,” said Nancy Cooper, Newsweek’s Global Editor in Chief.

This marks the fourth annual Most Loved Workplace list, and for 2024, the list has expanded to the Top 200, reflecting companies’ growing commitment to prioritizing employee sentiment and creating workplaces that employees love. Poseida was ranked #140 on the list. For the full list of the 2024 America’s Top 200 Most Loved Workplaces®, please visit Newsweek.

Methodology
To identify the top 200 companies in this list, companies were evaluated and scored as follows: 50 percent of the initial score was based on direct employee responses to BPI’s Love of Workplace Index assessment. 35 percent came from BPI’s direct interviews and written responses from company officials. The final 15 percent was derived from analysis of external public ratings from sites such as Comparably, Careerbliss, Glassdoor, Indeed, and Google. Newsweek then conducted editorial research on every company before the final list of 200 companies and their rankings was completed.

About Newsweek
Newsweek is the modern global digital news organization built around the iconic, over 90-year-old American magazine. Newsweek reaches 100 million people each month with its thought-provoking news, opinion, images, graphics, and video delivered across a dozen print and digital platforms. Headquartered in New York City, Newsweek also publishes international editions in EMEA and Asia.

About Best Practice Institute
Best Practice Institute is an award-winning leadership and organization development center, benchmark research company, think tank, and solutions provider. BPI is the only certifying body for Most Loved Workplace® and conducted the original research to create the model and criteria for becoming a Most Loved Workplace®. BPI’s research proves that Most Loved Workplaces® produce 3-4 times better customer service, employee performance, and retention than companies not loved by their employees. 

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company’s approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-named-to-newsweeks-list-of-the-top-200-americas-most-loved-workplaces-for-2024-302267219.html

SOURCE Poseida Therapeutics, Inc.

CHICAGO, Oct. 3, 2024 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), the world’s leading derivatives and securities exchange network, today reported September 2024 trading volume statistics across its global business lines and provided guidance for selected revenue per contract/net revenue capture metrics for the third quarter of 2024.

The data sheet “Cboe Global Markets Monthly Volume & RPC/Net Revenue Capture Report” contains an overview of certain September trading statistics and market share by business segment, volume in select index products, and RPC/net capture, which is reported on a one-month lag, across business lines.

September and Third Quarter 2024 Trading Volume Highlights   

U.S. Options

In the third-quarter, ADV for Cboe’s proprietary index options product suite reached an all-time high of 4.23 million contracts.Total volume in the third quarter in Cboe Volatility Index (VIX) options was 62.7 million contracts, with an ADV of 980 thousand contracts, the second-best quarterly volume on record.

Cboe Europe

Cboe Europe Periodic Auctions reported a monthly record average daily notional value (ADNV) of €2.4 billion in September, beating the previous record of €2.1 billion in April 2024.

Third-Quarter 2024 RPC/Net Revenue Capture Guidance

The projected RPC/net capture metrics for the third quarter of 2024 are estimated, preliminary and may change. There can be no assurance that our final RPC for the three months ended September 30, 2024, will not differ materially from these projections.

The above represents average revenue per contract (RPC) or net capture is based on a three-month rolling average, reported on a one-month lag. Average transaction fees per contract can be affected by various factors, including exchange fee rates, volume-based discounts and transaction mix by contract type and product type.

For Options and Futures, the average RPC represents total net transaction fees recognized for the period divided by total contracts traded during the period for options exchanges: BZX Options, Cboe Options, C2 Options and EDGX Options; futures include contracts traded on Cboe Futures Exchange, LLC (CFE).For U.S. Equities, “net capture per 100 touched shares” refers to transaction fees less liquidity payments and routing and clearing costs divided by the product of one-hundredth ADV of touched shares on BZX, BYX, EDGX and EDGA and the number of trading days for the period.For U.S. Equities – Off-Exchange, “net capture per 100 touched shares” refers to transaction fees less OMS/EMS costs and clearing costs divided by the product of one-hundredth ADV of touched shares on BIDS Trading and the number of trading days for the period.For Canadian Equities, “net capture per 10,000 touched shares” refers to transaction fees divided by the product of one-ten thousandth ADV of shares for Cboe Canada and the number of trading days for the period and includes revenue.For European Equities, “net capture per matched notional value” refers to transaction fees less liquidity payments in British pounds divided by the product of ADNV in British pounds of shares matched on Cboe Europe Equities and the number of trading days.For Australian Equities, “net capture per matched notional value” refers to transaction fees less trading fee relief in Australian Dollars divided by the product of ADNV in Australian Dollars of shares matched on Cboe Australia and the number of trading days.For Japanese Equities, “net capture per matched notional value” refers to transaction fees less liquidity payments in Japanese Yen divided by the product of ADNV in Japanese Yen of shares matched on Cboe Japan and the number of trading days.For Global FX, “net capture per one million dollars traded” refers to transaction fees less liquidity payments, if any, divided by the Spot and SEF products of one-thousandth of ADNV traded on the Cboe FX Markets and the number of trading days, divided by two, which represents the buyer and seller that are both charged on the transaction.For Cboe Clear Europe, “Fee per Trade Cleared” refers to clearing fees divided by number of non-interoperable trades cleared and “Net Fee per Settlement” refers to settlement fees less direct costs incurred to settle divided by the number of settlements executed after netting.

About Cboe Global Markets

Cboe Global Markets (Cboe: CBOE), the world’s leading derivatives and securities exchange network, delivers cutting-edge trading, clearing and investment solutions to people around the world. Cboe provides trading solutions and products in multiple asset classes, including equities, derivatives and FX across North America, Europe and Asia Pacific. Above all, we are committed to building a trusted, inclusive global marketplace that enables people to pursue a sustainable financial future. To learn more about the Exchange for the World Stage, visit www.cboe.com.

CBOE-V

Cboe®, Cboe Global Markets®, Cboe Volatility Index®, and VIX® are registered trademarks of Cboe Exchange, Inc. or its affiliates. Standard & Poor’s®, S&P®, SPX®, and S&P 500® are registered trademarks of Standard & Poor’s Financial Services, LLC, and have been licensed for use by Cboe Exchange, Inc. All other trademarks and service marks are the property of their respective owners.

Any products that have the S&P Index or Indexes as their underlying interest are not sponsored, endorsed, sold or promoted by Standard & Poor’s or Cboe and neither Standard & Poor’s nor Cboe make any representations or recommendations concerning the advisability of investing in products that have S&P indexes as their underlying interests. All other trademarks and service marks are the property of their respective owners.

Cboe Global Markets, Inc. and its affiliates do not recommend or make any representation as to possible benefits from any securities, futures or investments, or third-party products or services. Cboe Global Markets, Inc. is not affiliated with S&P. Investors should undertake their own due diligence regarding their securities, futures, and investment practices. This press release speaks only as of this date. Cboe Global Markets, Inc. disclaims any duty to update the information herein.

Nothing in this announcement should be considered a solicitation to buy or an offer to sell any securities or futures in any jurisdiction where the offer or solicitation would be unlawful under the laws of such jurisdiction. Nothing contained in this communication constitutes tax, legal or investment advice. Investors must consult their tax adviser or legal counsel for advice and information concerning their particular situation.

Cboe Global Markets, Inc. and its affiliates make no warranty, expressed or implied, including, without limitation, any warranties as of merchantability, fitness for a particular purpose, accuracy, completeness or timeliness, the results to be obtained by recipients of the products and services described herein, or as to the ability of the indices referenced in this press release to track the performance of their respective securities, generally, or the performance of the indices referenced in this press release or any subset of their respective securities, and shall not in any way be liable for any inaccuracies, errors. Cboe Global Markets, Inc. and its affiliates have not calculated, composed or determined the constituents or weightings of the securities that comprise the third-party indices referenced in this press release and shall not in any way be liable for any inaccuracies or errors in any of the indices referenced in this press release.

There are important risks associated with transacting in any of the Cboe Company products discussed here. Before engaging in any transactions in those products, it is important for market participants to carefully review the disclosures and disclaimers contained at: https://www.cboe.com/us_disclaimers/. 

Options involve risk and are not suitable for all market participants. Prior to buying or selling an option, a person should review the Characteristics and Risks of Standardized Options (ODD), which is required to be provided to all such persons. Copies of the ODD are available from your broker or from The Options Clearing Corporation, 125 S. Franklin Street, Suite 1200, Chicago, IL 60606. 

Cautionary Statements Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as “may,” “might,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.

We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our dependence on and exposure to risk from third parties; global expansion of operations; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our growth and strategic acquisitions or alliances effectively; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, counterparty, investment, and default risks, associated with operating a European clearinghouse; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing potential conflicts between our regulatory responsibilities and our for-profit status; our ability to maintain BIDS Trading as an independently managed and operated trading venue, separate from and not integrated with our registered national securities exchanges; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the impacts of pandemics; the accuracy of our estimates and expectations; litigation risks and other liabilities; and risks relating to digital assets, including winding down the Cboe Digital spot crypto market and transitioning digital asset futures contracts to CFE, operating a digital assets futures clearinghouse, cybercrime, changes in digital asset regulation, and fluctuations in digital asset prices. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2023 and other filings made from time to time with the SEC.

We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cboe-global-markets-reports-trading-volume-for-september-2024-302267258.html

SOURCE Cboe Global Markets, Inc.

IRVINE, Calif., Oct. 3, 2024 /PRNewswire/ — OrthAlign, Inc., a privately held medical device company, announces FDA 510(k) clearance of their Lantern Hip handheld technology for direct anterior total hip arthroplasty with the patient in the supine position. Lantern Hip is the latest addition to the Lantern platform, joining existing applications for total knee, revision knee, and partial knee arthroplasty.

Lantern Hip builds upon the legacy of HipAlign® with enhanced technology and usability. Next-generation accelerometers and gyroscopes offer orthopedic surgeons a streamlined workflow, real-time navigation for cup positioning, and restoration of leg length and offset. The technology enables individualized cup positioning compared across multiple planes, including the functional pelvic plane, anterior pelvic plane, and coronal plane, with live pelvic tracking. Designed for personalized patient care, Lantern Hip eliminates the need for pre-operative imaging or capital equipment and is compatible with most implant systems, making it an ideal choice for the ASC setting.

“Technologies like Lantern Hip represent the future of orthopedic surgery,” said Edwin Su, MD, orthopedic surgeon at the Hospital for Special Surgery in New York, NY. “The system provides the information I need to accurately position each patient’s hip components based on their unique anatomy, and I can hit the leg length and offset targets I want to achieve. These advancements, coupled with the new ability to place the cup in relation to the functional pelvic plane, hold the potential to greatly improve patient outcomes.”

“Adding the total hip application to the Lantern platform is an enhancement that not only broadens our capabilities, but also reinforces our commitment to providing innovative solutions,” said Eric Timko, Chairman and CEO of OrthAlign. “As technology becomes the standard of care in total joint replacement, it’s essential to deliver solutions that are clinically, operationally, and economically efficient. Lantern Knee and Balance have been a great success for OrthAlign and now, with Lantern Hip, surgeons can confidently and easily take technology to any site of service for their total hip replacements. I applaud our internal team and surgeon advisors for the countless hours spent developing a product that we expect will make a positive impact on healthcare.”

Lantern Hip will be on display at the American Association of Hip and Knee Surgeons (AAHKS) annual meeting in Grapevine, TX in November. To learn more, contact info@orthalign.com.

About OrthAlign, Inc.

OrthAlign is a medical device company with a focus on delivering practical, cutting-edge technologies for orthopedic surgery. With a commitment to innovation and excellence, OrthAlign provides surgeons with user-friendly, cost-effective solutions to help improve patient care in joint replacement. In 2023, the company celebrated a record-breaking year with over $50 million in global revenue, reflecting its dedication to growth and leadership in the industry.

Driven by the belief that everyone deserves exceptional healthcare, we are committed to making empowering technologies accessible to all.

For more information regarding OrthAlign, please visit www.orthalign.com.

HIPALIGN®, LANTERN®, and ORTHALIGN® are registered trademarks of OrthAlign, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/orthalign-receives-fda-510k-clearance-for-lantern-hip-302267260.html

SOURCE OrthAlign